Collaboration provides opportunity to expand on Alexion’s two decades of complement leadership Complement Pharma to receive up to a total of € 14 million in milestone-dependent payments through Phase ...

- Agreement provides Alexion with exclusive worldwide licenses for one preclinical target, with option for up to three additional targets, in the complement pathway - - Zealand Pharma to receive ...

The complement system is activated in many rheumatic diseases, as evident from deposition of activation fragments in affected tissue, decreased residual complement function and increased levels of ...